Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
+$1.50 today
- Market cap
- $10.34B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
Volume 0.68M
Average 0.58M
KYMR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Kymera Therapeutics, Inc.NASDAQ: KYMR
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$59.1M, compared with -$74.42M a year earlier. Trailing-twelve-month EBITDA was -$291.43M.
Context
- EBITDA amounted to 773.1% of revenue in FY2025, up 313.7 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 17 analysts of -$307.03M (-1.3%) for the fiscal year ending Dec 2026, a step up from the -40.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$59.1M+12.0% QoQ
- Last fiscal yearDec 2025
- -$303.06M-40.2% YoY
- LTMJun 2026
- -$291.43M-9.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +20.6% | -55.6% | -76.2 pp |
| 1 year | -40.2% | -1.3% | +38.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (303.06M) USD
- Year-over-year change
- -40.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (303.06M) | -40.2% |
| FY2024 | 2024-12-31 | (216.24M) | -51.0% |
| FY2023 | 2023-12-31 | (143.2M) | +5.6% |
| FY2022 | 2022-12-31 | (151.66M) | -55.3% |
| FY2021 | 2021-12-31 | (97.65M) | — |
EBITDA vs competitors
How KYMR compares with its peers on the latest reported figures
- KYMR's LTM Jun 2026 EBITDA of -$291.43M is the lowest of the 5 companies compared; the peer median is -$111.96M.
- Its year-over-year change of -9.1% is the 3rd highest of 5, against a peer median of -220.4%.
- EBITDA amounts to 277.6% of revenue for KYMR, versus a peer median of 264.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $322.61M | +243.1% | — | 46.0% | |
| LTM Mar 2026 | -$100.38M | -3.7% | — | 287.9% | |
| LTM Mar 2026 | -$123.54M | -796.7% | — | 287.6% | |
| LTM Mar 2026 | -$216.5M | -437.2% | — | 242.2% | |
| LTM Jun 2026 | -$291.43M | -9.1% | — | 277.6% | |
| Peer median (excluding KYMR) | -$111.96M | -220.4% | — | 264.9% | |
Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 137.02M | 164.25M | 189.08M | 240.25M | 316.6M |
| Selling, General & Admin | 36.35M | 43.83M | 55.04M | 63.53M | 68.2M |
| Operating Expenses | 173.36M | 208.08M | 244.12M | 308.71M | 388.6M |
| Depreciation & Amortization | 2.4M | 2.98M | 3.57M | 7.37M | 8.31M |
| EBITDA | (97.65M) | (151.66M) | (143.2M) | (216.24M) | (303.06M) |
| EBITDA Margin | -134.1% | -323.9% | -182.2% | -459.4% | -773.1% |
| Operating Income | (100.53M) | (161.26M) | (165.53M) | (261.64M) | (349.4M) |
| Operating Margin | -138.0% | -344.4% | -210.6% | -555.8% | -891.3% |
| Interest Income | 488K | 6.62M | 18.76M | 38.03M | 38.03M |
| Interest Expense | 175K | 176K | 196K | 249K | 249K |
| Other Income / Expenses | 313K | 6.45M | 18.57M | 37.78M | 37.78M |
| Income Before Tax | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.62M) |
| Pre-Tax Margin | -137.6% | -330.6% | -187.0% | -475.6% | -795.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.4M) |
| Net Margin | -137.6% | -330.6% | -187.0% | -475.6% | -794.4% |
| EPS (Basic) | (2.09) | (2.87) | (2.52) | (2.98) | (3.69) |
| EPS (Diluted) | (2.09) | (2.87) | (2.52) | (2.98) | (3.69) |
| Weighted Avg Shares | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M |
| Weighted Avg Shares (Diluted) | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M |
Kymera Therapeutics, Inc.
NASDAQ:KYMR
Intrinsic Alpha fair value
Locked
Current Price
$121.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.